Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Multiple Sclerosis

Multiple Sclerosis

Recruiting

GEMINI 1

The purpose of this study is to assess the efficacy of two drug treatments measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS.

Status
Recruiting
Principal Investigator
Virginia Devonshire
Body Locations and Systems
Brain
Multiple Sclerosis
Age
18 - 55

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (O'HAND)

The purpose of this study is to evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS).

Status
Recruiting
Principal Investigator
Alice Schabas
Body Locations and Systems
Multiple Sclerosis
Area
Vancouver
Age
18 - 65

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis (VISIONARY-MS)

The purpose of this study is to assess the efficacy and safety of CNM-Au8 as a remyelinating therapy in patients with stable relapsing-remitting multiple
sclerosis (RMS).

Status
Recruiting
Principal Investigator
Anthony Traboulsee
Body Locations and Systems
Multiple Sclerosis
Area
Vancouver
Age
18 - 55

Multiple Sclerosis, Genes, Microbes, and Medication

The purpose of the main study is to investigate adverse drug reactions from multiple sclerosis (MS) disease modifying drugs by understanding the genetic factors that contribute to their cause. 

The sub-study investigates how the MS disease modifying drugs affect microbes in the gut and how human DNA affects the changes in the gut microbes following drug treatment. We are also interested in how gut microbes might relate to progressive MS.

recruitment poster

Status
Recruiting
Principal Investigator
Helen Tremlett
Body Locations and Systems
Multiple Sclerosis
Immune System
Area
Vancouver
Age
18 and above

Correlation Between PET and Advanced MRI in Multiple Sclerosis

This is an observational study designed to determine the relationship between quantitative advanced MRI measures and OCT with PET measurements of microglial activation and myelin health. 

Status
Recruiting
Principal Investigator
Robert Carruthers
Body Locations and Systems
Multiple Sclerosis
Area
Vancouver
Age
18-60

Dysport 222

The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS).

Status
Recruiting
Principal Investigator
Lynn Stothers
Body Locations and Systems
Urinary Incontinence
Multiple Sclerosis
Spinal Cord Injury
Area
Vancouver
Age
18-80

Closed for Recruitment

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.

Status
Closed for Recruitment
Principal Investigator
Robert Carruthers
Body Locations and Systems
Multiple Sclerosis
Area
Vancouver
Age
18 - 55 years

Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)

The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment

Status
Closed for Recruitment
Principal Investigator
Virginia Devonshire
Body Locations and Systems
Multiple Sclerosis
Area
Vancouver
Age
18 - 65 years

Establishing an Imaging Biomarker for Disease Progression in Multiple Sclerosis

MS is a disabling neurological disease with a highly variable clinical course including acute disability (relapses when symptoms appear or worsen) and disease progression (steady accumulation of disability in the absence of relapses). There is currently no approved treatment for progressive MS. A principal pathology of MS is the destruction of myelin, which surrounds nerves to speed up signal conduction. We have developed a magnetic resonance imaging technique that provides quantitative measurements of myelin.

Status
Closed for Recruitment
Principal Investigator
Shannon Kolind
Body Locations and Systems
Multiple Sclerosis
Area
Vancouver
Age
18-65

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis (ASCLEPIOS I)

 

To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis.

Status
Closed for Recruitment
Principal Investigator
Robert Carruthers
Body Locations and Systems
Multiple Sclerosis
Area
Vancouver
Age
18-55

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

This is an exploratory biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-Cell biology in relapsing multiple sclerosis (RMS). 

Status
Closed for Recruitment
Principal Investigator
Robert Carruthers
Body Locations and Systems
Multiple Sclerosis
Area
Vancouver
Age
18-55

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT], 23-valent pneumococcal polysaccharide vaccine [23-PPV], influenza vaccine, and keyhole limpet hemocyanin [KLH]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).

Status
Closed for Recruitment
Principal Investigator
Anthony Traboulsee
Body Locations and Systems
Multiple Sclerosis
Area
Vancouver
Age
18-55

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with RRMS.

Status
Closed for Recruitment
Principal Investigator
Anthony Traboulsee
Body Locations and Systems
Multiple Sclerosis
Area
Vancouver
Age
18-55

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 (TOPAZ)

Primary Objective:

  • To evaluate long-term safety of alemtuzumab.

Secondary Objectives:

  • To evaluate long term efficacy of alemtuzumab. To evaluate the safety profile of patients who received other Disease Modifying Treatment's (DMT) following alemtuzumab treatment.
  • To evaluate patient-reported Quality of Life (QoL) outcomes and health resource utilization of patients who received alemtuzumab.
  • To evaluate as needed re-treatment with alemtuzumab and other DMTs.
Status
Closed for Recruitment
Principal Investigator
Anthony Traboulsee
Body Locations and Systems
Multiple Sclerosis
Area
Vancouver
Age
18 and above

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya (IGLOO)

This study will determine whether in RRMS patients receiving Gilenya there is a link between disease progression and biologic markers.

Status
Closed for Recruitment
Principal Investigator
Anthony Traboulsee
Body Locations and Systems
Multiple Sclerosis
Neurologic Diseases
Area
Vancouver
Age
18-65

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with Rebif (interferon beta-1a) in patients with relapsing multiple sclerosis. Patients will be randomized to receive either in group A, ocrelizumab 600 mg intravenously (iv) every 24 weeks plus Rebif placebo subcutaneously (sc) three times weekly, or, in group B, Rebif 8.8 mcg (Weeks 1+2)/22 mcg (Weeks 3+4)/44 mcg (Week 5 and following) sc three times weekly plus ocrelizumab placebo iv every 24 weeks. Anticipated time on study treatment is 96 weeks.

Status
Closed for Recruitment
Principal Investigator
Anthony Traboulsee
Body Locations and Systems
Multiple Sclerosis
Area
Vancouver
Age
18-55

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 (EXTEND)

The primary objective of the study is to assess the safety and tolerability of long-term treatment with BIIB019 (Daclizumab High Yield Process; DAC HYP) monotherapy in participants with relapsing remitting multiple sclerosis (RRMS) who completed Study 205MS301 (NCT01064401).

The secondary objectives of this study in this study population are as follows:

Status
Closed for Recruitment
Principal Investigator
Anthony Traboulsee
Body Locations and Systems
Multiple Sclerosis
Area
Vancouver
Age
18 and above

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo. The blinded treatment period will be at least 120 weeks, followed by an Open Label Extension (OLE) treatment for participants in both groups who in the opinion of the investigator could benefit from further or newly initiated ocrelizumab treatment.

Status
Closed for Recruitment
Principal Investigator
Anthony Traboulsee
Body Locations and Systems
Multiple Sclerosis
Area
Vancouver
Age
18-55

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

The purpose of this study is to collect long-term safety and tolerability, long-term efficacy, and health outcome data in all patients currently ongoing in the fingolimod multiple sclerosis clinical development program. This study will combine all currently ongoing Phase II and III fingolimod extension studies as well as ongoing and newly planned studies into one single long-term extension protocol that will provide patients with continuous treatment and will continue until fingolimod is registered, commercially available, and reimbursed in the respective countries.

Status
Closed for Recruitment
Principal Investigator
Virginia Devonshire
Body Locations and Systems
Multiple Sclerosis
Area
Vancouver
Age
18 and above
Subscribe to Multiple Sclerosis

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy